['chronic myeloid leukemia']
['nilotinib (tasigna ®), capsules of 150 mg', 'nilotinib (tasigna ®) and pegylated interferon alfa 2a (pegasys®)']

        Inclusion Criteria:

          -  Male and female patients

          -  CP-CML, positive Philadelphia chromosome or positive BCR-ABL (M-bcr transcript),
             diagnosed less than 3 months prior to study entry

          -  Age of at least 18 years-old and less than 65 years

          -  Patient for whom treatment with Nilotinib is expected

          -  No other CML treatment except for hydroxyurea and/or anagrelide

          -  No previous TKI treatment.

          -  No previous treatment with IFN even for other purposes.

          -  SGOT and SGPT < 2.5 UNL

          -  Serum creatinine < 2 UNL

          -  No planned allogeneic stem cell transplantation

          -  Signed informed consent

          -  ECOG score 0 to 2

        Exclusion Criteria:

          -  Contra-indication to IFN

          -  Transcripts other than M-Bcr

          -  Pregnancy, lactation

          -  HIV positivity, chronic hepatitis B or C.

          -  Prior or concurrent malignancy other than CML (exceptions to be mentioned)

          -  History of arterial occlusive disease or (peripheral, carotids or severe coronary
             heart disease).

          -  Permanent elevation of total cholesterol and triglycerides despite treatment

          -  Severe psychiatric/neurological disease (previous or ongoing)

          -  Concomitant auto-immune disease

          -  Other investigational product ongoing

          -  Ongoing immunosuppressive treatment

          -  Ongoing treatment at risk for inducing torsades de pointes

          -  QTcF > 450ms despite correction of predisposing factors (i.e electrolytes…)

          -  Congenital long QTcF

          -  Unstabilised thyroid disorder

          -  No health insurance coverage
      